Immune thrombocytopenia (ITP) involves impaired platelet production with complex underlying immune dysregulation. Current therapies offer inconsistent efficacy and unresolved quality of life concerns. Rilzabrutinib, an oral BTK inhibitor recently ap...
HYMPAVZI ® (marstacimab) PFIZER HK Reg. No. HK-68832 (28 Aug, 2025) Composition: 3 • Hympavzi 150 mg solution for injection in pre-filled pen: Each pre-filled pen contains 150 mg marstacimab in 1 mL of solution Indication: 3 Hympavzi is ind...
APIXABAN TEVA ® (apixaban) TEVA HK Reg. No. HK-68762 (16 Jul, 2025) Composition: 4 • Each film-coated tablet contains 2.5 mg apixaban Indication: 4 • Prevention of venous thromboembolic events (VTE) in adult patients who have undergone...
Paradigm Shift in Management of Unresectable Hepatocellular Carcinoma (uHCC) In Hong Kong, liver cancer is the fifth most common cancer (with 1,771 new cases of liver cancer reported in 2021) and the third most common cause of cancer-related deaths ...
Chronic Lymphocytic Leukaemia (CLL) is a lymphoproliferative disorder characterised by the expansion of monoclonal, mature CD5+ CD23+ B cells in the peripheral blood, secondary lymphoid tissues, and bone marrow 1 . The molecular heterogeneity of CLL...
Principles for Treatment Selection The newly established European guidelines advocate IMiD-based therapies as the induction therapy for patients with newly diagnosed multiple myeloma (NDMM), regardless of eligibility for autologous stem cell transpl...
The management of relapsed and refractory multiple myeloma (RRMM) continues to be challenging though new therapeutics for the disease have been emerging in recent decades. Essentially, while decreased survival was observed in each extra line of ther...
Currently Available Therapeutic Options for MM MM is currently one of the most prevalent haematological malignancies, which mainly affects individuals aged above 65 2 , a relatively vulnerable group of patients owing to comorbidities and immunosenes...
The Multitude of Activities of IMiDs Because of the established benefits, IMiDs are recommended as induction therapy for both transplant eligible and ineligible patients, in the post-transplant maintenance setting, and for relapsed/refractory diseas...
Background Information The patient of the current case was a 64-year-old male with documented ischemic heart disease and received 3 times of percutaneous coronary intervention (PCI), respectively in 2004, 2005 and 2013. In 2015, the patient complain...
Reduced Overall Survival in Refractory MM Although the application of the first IMiD, lenalidomide, had significantly increased median overall survival (OS) 2 , Prof. Leleu commented that the treatment success was hindered by the refractoriness of M...
